Dialysis & Transplantation最新文献

{"title":"Retracted Fenoldopam in critically ill patients with early renal dysfunction: A crossover study","authors":"Gian Paparcuri MD,&nbsp;Miguel Cobas MD,&nbsp;Maria De La Pena MD,&nbsp;Erik Barquist MD,&nbsp;Albert Varon MD","doi":"10.1002/dat.20538","DOIUrl":"10.1002/dat.20538","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Retraction: The following article from <i>Dialysis &amp; Transplantation</i>, 'Fenoldopam in critically ill patients with early renal dysfunction: A crossover study' by Gian Paparcuri, Miguel Cobas, Maria De La Pena, Erik Barquist and Albert Varon, published online on March 8, 2011 in Wiley Online Library (wileyonlinelibrary.com), and in Volume 40, pp. 164-167, has been retracted through agreement between the first author, the Editors, Andrew Z. Fenves and Larry B. Melton, and Wiley Periodicals, Inc. The retraction has been agreed due to duplicate publication in another journal.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 4","pages":"164-167"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20538","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"My most memorable patient","authors":"John Larsen CHT","doi":"10.1002/dat.20549","DOIUrl":"10.1002/dat.20549","url":null,"abstract":"<p>I have worked as a certified hemodialysis technologist/technician (CHT) for about 12 years, and have been in the medical field for almost 20. I've worked with many extraordinary patients over the years, but I have one particular patient who was very special to me—my dad.</p><p>Dad went into the hospital to have an aneurysm on his aorta removed. It had been there for years, and we all knew it. It was a triple “A” surgery (abdominal aortic aneurysm) that ended up with a fourth aneurysm found in his groin area that exploded throughout his left leg. To make a long story short, Dad lost circulation in his left leg which then had to be removed below the knee. Then what I thought was my worst nightmare occurred—his kidneys shut down. We had to make another traumatic decision, to start dialysis right away.</p><p>I helped set up the machine, and while stringing it I took measures and precautions beyond those I typically do with patients to ensure sterilization because, after all, this was my dad. The catheter placement wasn't the best, but I helped get the dialysis going and, as I sat there watching him, I knew Dad wouldn't want to live like that. But, I took every measure I could to make him comfortable, telling myself it was just an acute setting and that he would bounce back.</p><p>During this time that my father was ill, the company I work for had offered me a biomedical position—a job that would take me away from direct patient care—which I was considering. My dad and I were always close, and he was always my hero. He always listened to me and helped me make decisions about different things in my life, and I always went to him for advice. Sitting there with my dad in the hospital, I started to think about all of the patients in my dialysis facility—how they feel, all they go through as dialysis patients, and all of the tough decisions they have to make.</p><p>As I had in the past, I took this time talked to my dad about the opportunity, even though I wasn't sure he couldn't hear me as he lay there in the hospital bed. I told him about the offer and, even though he could not talk because of his ventilator, he raised his arm, put his hand on mine, and shook his head “no.” I said, “Dad, do you want me to stay with the patients?” And he nodded his head “yes.”.</p><p>This was a very moving moment for me, and I immediately decided to decline my company's offer and stay with patient care. When you set up patients every day, it's easy to become mechanical and just go through the motions. But I now look at every patient as if he or she is my dad, and am careful to string a machine and hook up every patient with the same care and precision as if my dad was in that chair.</p><p>My father passed away three years ago. I loved him very much, and I miss him terribly, but he helped me make a decision I've never been sorry for. Thank you, Dad. You were my favorite patient. Love, your son, John.</p>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"136"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20549","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excellent outcomes of renal transplantation in patients 70 years of age or older","authors":"James V. Guarrera MD,&nbsp;Benjamin Samstein MD,&nbsp;Fahad Aziz MD,&nbsp;Joan Kelly RN,&nbsp;Mark A. Hardy MD,&nbsp;Lloyd E. Ratner MD","doi":"10.1002/dat.20545","DOIUrl":"10.1002/dat.20545","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> BACKGROUND</h3>\u0000 \u0000 <p>The survival benefit of renal transplantation is well established. As the average life expectancy increases, so too will the average age of renal transplant patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>We reviewed our experience with renal transplantation in patients 70 years of age and older. Fifty patients aged 70 years and older were transplanted at our institution between 1997 and 2007. Demographics and outcomes were recorded retrospectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>The mean age of the cohort was 73.1 years (range, 70–80 years). Among the 50 transplanted allografts, 32 (64%) were from deceased donors, and 18 (36%) were from living donors. At last follow-up, 45 (90%) patients were alive and 43 (86%) grafts were functioning. Median survival was 6.42 years. Five patients (10%) died, three from sepsis, one from cytomegalovirus infection, and one from myocardial infarction and stroke. There was no difference in the frequency of diabetes or hypertension compared with younger recipients in our institution during the same time period. Mean serum creatinine levels at 3 months, 6 months, 1 year, 2 years, and 3 years of fol-low-up were, respectively, 1.8 ± 0.97 (<i>n</i> = 41), 1.8 ± 1.3 (<i>n</i> = 33), 1.5 ± 0.4 (<i>n</i> = 25), 1.6 ± 0.45 (<i>n</i> = 16), and 1.5 ± 0.37 (<i>n</i> = 6) mg/dL. There were no statistically significant differences in acute cellular rejection between dif-ferent induction regimens. There were two grafts lost to rejection and fewer infections in the interleukin-2 receptor blocker group compared with the thymoglobulin group (<i>p</i> = NS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> CONCLUSIONS</h3>\u0000 \u0000 <p>Renal transplantation in patients 70 years of age and older is associated with excellent patient and graft survival, similar to rates in younger recipients. Advanced age should not be a contraindication to renal transplantation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"124-125"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20545","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research 101: Terms to help you understand research results","authors":"Dori Schatell MS,&nbsp;Peter Laird MD","doi":"10.1002/dat.20550","DOIUrl":"10.1002/dat.20550","url":null,"abstract":"<p>Dialysis is a fast-moving field and new, important studies come out each month. When you understand some of these common research terms, you'll be better equipped to know what the results may mean for your patients.</p>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"133-134"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20550","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deceased-donor kidney transplant following ethylene glycol-induced brain death","authors":"Nicole Sifontis PharmD,&nbsp;Richard Kim MD,&nbsp;Mark Birkenbach MD,&nbsp;Iris Lee MD,&nbsp;Serban Constantinescu MD,&nbsp;Andreas Karachristos MD,&nbsp;Patricio Silva MD,&nbsp;John Daller MD","doi":"10.1002/dat.20537","DOIUrl":"10.1002/dat.20537","url":null,"abstract":"<p>We report on a deceased-donor kidney transplant following ethylene glycol-induced brain death. The donor was a 53-year-old man with a history of depression who presented to the emergency department after drinking a “cocktail amount” of windshield wiper fluid each day for the past 3 weeks. Upon presentation he became unresponsive and suffered a seizure. Fomepizole 1.2 g IV followed by emergent hemodialysis was initiated as indicated for acute treat-ment of ethylene glycol poisoning. Unfortunately, the patient never regained consciousness and progressed to brain death. At the time of procurement his urine output was over 250 mL/h, and serum creatinine was 2.2 mg/dL. Renal biopsy following procurement revealed minimal tubule injury without evidence of intratubular oxalate crystals. The kidney recipient was a 76-year-old woman with end-stage renal disease secondary to diabetes and hypertension. Cold ischemia time was 31 hours, 45 minutes. The only postoperative complication was delayed graft function and one episode of mild acute cellular rejection 7 weeks post transplant that resolved with IV methylprednisolone. Two years post transplant the patient continues to do well clinically with a baseline serum creatinine of 2.5 mg/dL.</p>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"126-128"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20537","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amino acid removal in high-flow and conventional continuous hemodiafiltration","authors":"Kazushige Oishi MD,&nbsp;Satoshi Hagiwara MD, PhD,&nbsp;Satoko Koga MD,&nbsp;Satoshi Kawabe MD,&nbsp;Takahiro Uno MD, PhD,&nbsp;Koji Goto MD, PhD,&nbsp;Takayuki Noguchi MD, PhD","doi":"10.1002/dat.20546","DOIUrl":"10.1002/dat.20546","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> OBJECTIVE</h3>\u0000 \u0000 <p>Continuous hemodiafiltration is frequently used in intensive care as renal replacement therapy for acute kidney damage. Recent studies have shown that increased flow rates can effectively increase survival. However, continuous hemodiafiltration also removes essential small molecules such as amino acids.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>We compared amino acid loss between conventional (normal-flow) and high-flow continuous hemodia-filtration in 17 patients admitted to the intensive care unit for conditions such as sepsis. Patients were randomly divided into a normal-flow group (dialysate flow, 500 mL/min; filtrate flow, 300 mL/min; and blood flow, 80 mL/min) and a high-flow group (dialysate flow, 1,500 mL/min; filtrate flow, 900 mL/min; blood flow, 100 mL/min). Blood samples were collected immediately prior to continuous hemodiafi initiation, and at 2 and 6 hours after con-tinuous hemodiafiltration initiation. In addition, blood and filtrate were collected from the circuit in front of and behind the continuous hemodiafiltration dialyzer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>We found that amino acid removal was significantly higher in the high-flow group and that amino acids were removed into the filtrates in proportion to their plasma concentrations. Furthermore, plasma amino acid con-centrations also tended to decrease with the length of time continuous hemodiafiltration was performed. Given that large amounts of amino acid are removed during continuous hemodiafiltration, plasma amino acid levels should be monitored when prolonged continuous hemodiafiltration is performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> CONCLUSIONS</h3>\u0000 \u0000 <p>Amino acid loss is particularly high during high-flow continuous hemodiafiltration, suggesting that it may be necessary to shorten the duration of high-flow continuous hemodiafiltration or supplement patients with sufficient amounts of amino acids.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"110-117"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The D&T Report","authors":"","doi":"10.1002/dat.20551","DOIUrl":"https://doi.org/10.1002/dat.20551","url":null,"abstract":"<p>As the worldwide burden of renal disease increases, it appears that the public's willingness to donate their organs is also growing: According to a 2009 survey by L.D. Horvat, MD and colleagues in the Donor Nephrectomy Outcomes Re-search (DONOR) Network, rates of living donor kidney transplantation have steadily risen in most regions of the world, increasing its global significance as a treatment option for kidney failure. In 2006, the latest year for which numbers are available, 27,000 live-donor transplants were performed around the world. As shown in Table I, Americans donated the greatest number of kidneys in absolute terms, but Saudi Arabians were most altruistic on a perpopulation basis.<span>1</span>\u0000 </p><p>However, the supply of available kidneys from both live and deceased donors still falls greatly short of demand. In 2006, there were roughly 70,000 people on the wait list for organ donors in the United States alone, according to the U.S Renal Data Service. Similar scenarios exist in other countries. Currently, more than 50% of transplanted kidneys in the U.S. are from deceased donors and approximately 90% of these recipients would have undergone dialysis for three to five years prior to receiving that deceased- donor organ. <span>2</span></p><p>Many of the attempts to increase organ availability focus on broadening the donor pool. In trends such as expanded-criteria donors (ECD) and donation after cardiac death (DCD), kidneys are taken from people who are older and whose health may not be as good as standard-criteria donors (SCD), but whose organsmight still be viable for patients who are themselves older or sicker than average. The blessings associated with ECD kidneys are mixed: Patients who receive those organs live longer than people who remain on dialysis, but not as long as patients transplanted with SCD kidneys. In fact, compared with dialysis, the projected average number of added life-years associated with an SCD kidney is 10 years, but only 5.1 years for an ECD organ. The differences become especially stark with the passage of time: at 5 years post-transplant, average patient survival is 82% with SCD organs and only 70% with ECD organs, and graft survival is 65% and 49%, respectively. No such differences exist in comparisons between donation after brain death (DBD) and DCDkidneys. <span>2</span></p><p>Since 1996, some surgeons have transplanted both kidneys from donors who are particularly marginal. Dualkidney transplants (DKTs) now account for about 2% of all renal transplants performed in the U.S., or about 320 transplants per year. The criteria for a DKT donor is relatively loose, as long as the donor does not have cancer orAIDS. For example, in a DKT procedure performed at the University of Kansas Hospital in Kansas City last November, the donor was 75 at the time of death and had a history of hypertension and stroke. In this case, the recipient was 88 years old and also hypertensive. Such a patient would p","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"96-100"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20551","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137807225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-renal transplant plasma cell dyscrasia presenting as retroperitoneal plasmacytoma: A case report and literature review","authors":"Mahvish Muzaffar MD,&nbsp;Rekha Chaudhary MD,&nbsp;Xin Li MD,&nbsp;Shobha Ratnam MD","doi":"10.1002/dat.20539","DOIUrl":"10.1002/dat.20539","url":null,"abstract":"<p>Post-transplant lymphoproliferative disease (PTLD) is a rare but potentially fatal complication of organ transplanta-tion. Most cases of PTLD represent Epstein Barr virus (EBV)-related B-cell disease in a setting of pharmacological immunosuppression. Post-transplant plasma cell dyscrasia is very rare, and post-transplant plasma cell dyscrasia with extramedullary plasmacytoma is extremely rare. We report here a case of the latter, which to our knowledge is the fourth such reported case in the English literature. A 22-year-old man developed post-transplant plasma cell dyscrasia 20 years after a renal transplant while on immunosuppression. His presentation included retroperitoneal plasmacytoma, which is very rare and is probably the first case in a renal transplant patient. The patient is in complete remission 1 year after receiving five cycles of bortezomib and dexamethasone.</p>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"130-132"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20539","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51497953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BK virus infection after renal transplantation","authors":"Puneet Sood MD,&nbsp;Sundaram Hariharan MD","doi":"10.1002/dat.20544","DOIUrl":"https://doi.org/10.1002/dat.20544","url":null,"abstract":"<p>In this review, we will discuss updates in diagnosis, treatment, and primary prevention, as well as unresolved issues and future directions for BK virus nephropathy in renal transplant patients.</p>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"102-107"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20544","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137807226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of some risk factors of coronary and valvular calcification in peritoneal dialysis","authors":"Lucyna Janicka MD, PhD,&nbsp;Dariusz Duma MD, PhD,&nbsp;Agnieszka M. Grzebalska MD, PhD,&nbsp;Elzbieta Czekajska-Chehab MD, PhD,&nbsp;Andrzej Drop MD, PhD,&nbsp;Grzegorz Staskiewicz MD, PhD,&nbsp;Krzysztof Janicki MD, PhD,&nbsp;Janusz Solski MD, PhD,&nbsp;Andrzej Książek MD, PhD","doi":"10.1002/dat.20547","DOIUrl":"10.1002/dat.20547","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> OBJECTIVE</h3>\u0000 \u0000 <p>Our study was performed to analyze risk factors for coronary artery calcification (CAC) and valvular calcification (VC) in peritoneally dialyzed patients, as well as the frequency of fatal cardiovascular complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>The study was performed on 102 peritoneal dialyzed patients (mean time of dialysis: 37.3 ± 23 months). Patients were divided depending on the severity of calcification into three groups: A, lack of calcification; B, CAC up to 400 mm³; and C, CAC &gt;400 mm³. CAC and VC were measured by means of computed tomography. The following risk factors for CAC and VC were analyzed: age, gender, time of peritoneal dialysis, and levels of calcium, phosphates, calcium × phosphorus product (Ca × P), C-reactive protein (CRP), fibrinogen, fetuin-A, and parathormone (PTH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>Positive correlation was found between CAC and VC expressed by Agatston and volumetric score, and serum levels of CRP and fibrinogen and patient age. In patients with CAC and VC, serum levels of phosphorus and Ca × P were significantly higher; however, such significance was not observed in patients with CAC only. Serum fetuin-A was decreased in all study groups, and was significantly lower in patients with CAC and VC than in patients with CAC only. Cardiovascular complications were significantly more frequent and mortality was higher in group C than in groups A and B.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> CONCLUSIONS</h3>\u0000 \u0000 <p>In peritoneally dialyzed patients, CAC accompanied by VC is a high risk factor for mortality resulting from cardiovascular complications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 3","pages":"118-122"},"PeriodicalIF":0.0,"publicationDate":"2011-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20547","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51498430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}